Search

everythinglearnresearchcommunity

for

Search:↓

5α-reductase inhibitors may worsen sexual drive and spontaneous erections but don't worsen existing erectile or ejaculatory problems.

5-alpha reductase inhibitors may reduce bladder cancer recurrence and improve survival.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Finasteride and dutasteride have little effect on Type 2 Diabetes risk.

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Taking 5-Alpha Reductase Inhibitors before bladder removal surgery might make high-grade bladder tumors less aggressive.

5-alpha-reductase inhibitors help treat urinary symptoms from an enlarged prostate.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Finasteride may reduce prostate cancer spread by lowering certain enzyme levels.

Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.

IsoPSA test works accurately even if patients take certain prostate medications.

Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.

5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.

Hormones and metabolism play a complex role in prostate enlargement, and more research is needed to improve diagnosis and treatment.

Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.

COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.

Dutasteride caused more penile tissue changes than finasteride, possibly increasing erectile dysfunction risk.

5-alpha reductase inhibitors, like finasteride and dutasteride, may cause depression, but more research is needed to understand why.

Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.

5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.

Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.

The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

Personalized hair loss treatments are needed for transgender individuals, but more research is required.

Frontal fibrosing alopecia in men is often misdiagnosed and needs better diagnostic criteria and treatment strategies.

5-Alpha Reductase Inhibitors are effective for male hair loss and some skin conditions, but their effectiveness in women and safety concerns require careful use.

Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.